Kurv Yield Premium Strategy Tesla (TSLA) ETFTSLP
TSLP
0
Funds holding %
of 7,324 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1.21% more ownership
Funds ownership: 0% [Q4 2024] → 1.21% (+1.21%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for TSLP.
Financial journalist opinion
Positive
Zacks Investment Research
6 months ago
5 Top-Performing Dividend ETFs of 2H Yielding At Least 20%
High-yield ETFs provide investors with avenues to compensate for capital losses, if they occur at all.

Positive
Zacks Investment Research
7 months ago
Tesla Stock Hits All-Time High: ETFs to Ride the Momentum
Tesla shares hit an all-time high. Several analysts raised price targets.

Neutral
Business Wire
8 months ago
Kurv Investment Management Completes Reorganization of Yield Premium Suite to Proprietary Trust
SAN FRANCISCO--(BUSINESS WIRE)--Kurv Investment Management, an ETF provider of tax-efficient, institutional-grade investment strategies, announces the successful reorganization of its Yield Premium Suite ETFs into the Kurv ETF Trust. This transition marks a significant milestone in the company's growth and operational evolution. The Yield Premium Suite includes: Kurv Yield Premium Strategy Amazon (AMZN) ETF Kurv Yield Premium Strategy Apple (AAPL) ETF Kurv Yield Premium Strategy Google (GOOGL).

Neutral
Business Wire
11 months ago
Kurv Announces Special Distributions
SAN FRANCISCO--(BUSINESS WIRE)--Kurv Announces Special Distributions.

Neutral
Business Wire
1 year ago
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA).

Charts implemented using Lightweight Charts™